DaVita Inc. (NYSE:DVA) Given Consensus Recommendation of “Hold” by Brokerages

DaVita Inc. (NYSE:DVA) has earned an average rating of “Hold” from the seven analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $155.80.

A number of analysts have commented on DVA shares. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. UBS Group raised their price target on shares of DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. TD Cowen restated a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. Finally, Truist Financial set a $158.00 target price on shares of DaVita in a research report on Thursday, February 5th.

DaVita Price Performance

DaVita stock traded down $0.83 during mid-day trading on Friday, reaching $155.93. The stock had a trading volume of 37,154 shares, compared to its average volume of 1,096,871. DaVita has a one year low of $101.00 and a one year high of $159.42. The company has a 50-day moving average price of $139.33 and a two-hundred day moving average price of $128.07. The company has a market capitalization of $10.42 billion, a price-to-earnings ratio of 15.73, a PEG ratio of 0.54 and a beta of 0.94.

DaVita (NYSE:DVA) last issued its earnings results on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same period in the previous year, the company earned $2.24 earnings per share. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities research analysts anticipate that DaVita will post 10.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DaVita

Institutional investors have recently made changes to their positions in the business. Gen Wealth Partners Inc increased its holdings in DaVita by 10.0% during the fourth quarter. Gen Wealth Partners Inc now owns 880 shares of the company’s stock valued at $100,000 after buying an additional 80 shares during the last quarter. MAI Capital Management increased its stake in shares of DaVita by 23.4% in the 2nd quarter. MAI Capital Management now owns 438 shares of the company’s stock worth $62,000 after purchasing an additional 83 shares in the last quarter. NewEdge Advisors LLC raised its holdings in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock worth $78,000 after purchasing an additional 88 shares during the period. Orion Porfolio Solutions LLC lifted its position in DaVita by 4.4% during the fourth quarter. Orion Porfolio Solutions LLC now owns 2,360 shares of the company’s stock valued at $268,000 after purchasing an additional 99 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in DaVita by 34.9% in the third quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock worth $59,000 after buying an additional 117 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.